RecruitingNCT07174388
A Study in Non-Small Cell Lung Cancer
A Prospective Study to Generate Precision External Controls in Advanced or Metastatic Non Small Cell Lung Cancer Patients
Sponsor
N-Power Medicine
Enrollment
550 participants
Start Date
Jan 7, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
A study to create control arms using current and future information in patients with lung cancer that has spread who have already received chemotherapy.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This observational study is collecting data from real patients with non-small cell lung cancer (NSCLC) who are receiving second- or third-line treatments. It aims to build a dataset to better understand how these patients respond to treatment in everyday clinical practice (not in a controlled trial setting).
**You may be eligible if...**
- You are over 18 years old with confirmed NSCLC
- You are fit enough for further treatment and are receiving or about to start second-line therapy
- You have a life expectancy of more than 3 months and can give informed consent
**You may NOT be eligible if...**
- You cannot give informed consent
- You are currently enrolled in another interventional clinical trial
- Your baseline imaging scans do not meet the protocol's required format
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07174388
Related Trials
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT034128771 location
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
NCT066944541 location
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137260 locations
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143207 locations
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
NCT056578739 locations